Research

Communication and Advancement Awards Report Fiscal Year 2001
Medical Center Area
Medicine
McDowell Cancer Network

Primary Total: $6,122,240.
 Collaborative Total: $6,346,211.

ALFRED COHEN
American College of Surgeons Oncology Group, (464552), American College of Surgeons Research Fellowship, $9,333.00

ALFRED COHEN/CHANGQING XUN
Non-Chytotoxic Conditioning for Allogeneic Stem Cell Transplant, (464512), Natl Marrow Donor Program, $35,000.00

AVINDRA NATH/JEROLD WOODWARD/JIAYOU ZHANG
* Interactions of HIV-1gp120 with Brain Cells: Role of Pag, (463329), Natl Institute of Neurological Disorders & Stroke, $223,971.00

DEBRA ARMSTRONG
Community Cancer Coalitions, (464028), KY Department for Public Health, $27,280.00

EDWARD ROMOND
STAR Trial Breast Cancer Prevention Trial (P-2), (463505), NSABP Fdtn, $58,750.00

EDWARD ROMOND
NSABP Master Agreement, (461778), NSABP Fdtn, $59,560.00

EDWARD ROMOND
NSABP - A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer, (426051), NSABP Fdtn, $6,190.00

ERIC DURBIN
KCR Data Matching Project, (464673), KY Department for Public Health, $5,000.00

JIAYOU ZHANG
Mutation and Recombination of Retroviruses, (461162), Natl Cancer Institute, $103,190.00

JOHN YANNELLI/EDWARD HIRSCHOWITZ
CTL Defined Antigens in Non Small Cell Lung Cancer, (463151), Natl Cancer Institute, $271,932.00

MICHAEL DOUKAS
Randomized, Double-Blind, Placebo-controlled, Phase III Study of the Matrix Metalloproteinase Inhibitor AG3340 in Combination with Mitoxantrone and Prednisone in patients having Metastatic Hormone-Refractory Prostate Cancer, (461939), Agouron Pharmaceuticals, $29,600.00

PAMELLA SHAW/DONALD FRAZIER
Kentucky-Appalachian Science Enrichment Program, (461721), Natl Cancer Institute, $383,043.00

PATRICK MCGRATH
Southwest Oncology Group Studies, (462598), Southwest Oncology Group, $16,125.00

PAUL SLOAN
Open Label, Sequential Crossover Evaluation of the Analgesic Dose Equivalence, Efficacy and, (463452), Scirex, $20,138.00

PHILIP DESIMONE
Phase III Study of RFS vs. Gemcitabine HCL in Chemonaive Pancreatic Cancer Pts., (463973), Global Health Network, $2.00

PHILIP DESIMONE
Phase III Randomized Study of RFS 2000 Vs 5-Flourouracil in Pancreatic Can. Pts., (463974), Global Health Network, $2.00

PHILIP DESIMONE
Phase III of RFS 2000 vs. Most Appropriate Therapy in Refractory Pancreatic Cancer, (463975), Global Health Network, $2.00

PHILIP DESIMONE
98-LUN-37BP Randomized, Double-blind, Multi-Center, Placebo Controlled Study Comparing Single Agent, (462346), Bayer Pharmaceuticals, $3,375.00

PHILIP DESIMONE
96-GI-32SW: (Protocol EFC2970) A Multi-Center Study Evaluating the Addition of Oxaliplatin to 5-Fluorouracil Based Chemotherapy in Subjects with Advanced Refractory Colorectal Cancer, (460492), Sanofi Winthrop Inc, $4,000.00

PHILIP DESIMONE
A Phase II Study of Oral Xeloda in Combination with Intravenous Irinotecan for Patients with Locally Advanced and/or Metastatic Colorectal Cancer, (464681), Roche Laboratories, $2.00

PHILIP DESIMONE
00-GI-57SSR:A Multicenter, Open-Label, Randomized, Three-arm Study of 5-FU Plus Leucovorin or Oxaliplatin or a Combination of 5FU/LV + Oxaliplatin as 2nd-line Treatment of Metastatic Colorecal Carcinoma, (464769), Sanofi Synthelabo Inc, $2.00

PHILIP DESIMONE/JUSTINE YONEDA
Phase II Randomized Study of Taxol, Paraplatin and Radiation Therapy for Locally Advanced Inoperable Non-small Cell Lung Cancer, (462293), American College of Radiology, $3,100.00

PHILIP DESIMONE/KENNETH FOON
96-GI-41SW: A Phase II, Randomized, Multicenter Comparison of the Efficacy of Oxaliplatin in Four Schedules of 5- Fluorouracil with and without Leucovorin in Previously Untreated Advanced Colorectal Cancer, (461030), Sanofi Winthrop Inc, $40,000.00

RANDALL ROWLAND
SWOG-9217, Chemoprevention of Prostate Cancer with Finasteride (Proscar) Phase III, (427583), Southwest Oncology Group, $73,765.00

RICHARD GREENBERG
96-SC-05SP(SEQU-07-26/B): A Double-Blind, Randomized Study Comparing ABCD (Amphotericin B Colloidal Dispersion) and Fungizone in the Treatment of Febrile Neutropenic Patients Failing Broad Spectrum Antibacterial Therapy, (460740), Sequus Pharmaceuticals, $3,100.00

RITA MUNN
A Randomized, Double-Blind, Multicenter Study of Low- Dose Gallium Nitrate for Treatment of Bone Metastases Due to Breast Cancer, (429626), SoloPak Pharmaceutical Inc, $3,000.00

RITA MUNN
98 BRE 33 (98 BRE 33) Protocol No. B98 1290 (TAX/MEN.10) A Multicenter, Open Label, Randomized Study of Three Schedules of Weekly Taxol Induction Therapy Followed by Weekly Taxol, (462664), Theradex, $998.00

ROGER FLEISCHMAN
Anti-Id Protocols with Titan Pharmaceuticals, (463664), Titan Pharmaceuticals Inc, $24,680.00

ROGER FLEISCHMAN
00-MHL-15 Randomized, Double-Blind, Placebo-Controlled, Trial of Primary Prophylaxis with rh-TPO Administered to Patients Receiving DHAP Chemotherapy for Non-Hodkin's Lymphoma, (464279), Pharmacia & Upjohn Inc, $2.00

ROGER FLEISCHMAN
A Phase IV, Open-Label, Multicenter, Randomized Study of NEUMEGAR (Recombinant Human Interleukin Eleven Growth Factor, rhIL-11) in Patients with Lymphoma and Chemotherapy, (464420), Genetics Institute, $2.00

STEPHEN WYATT
Breast Cancer Task Force, (464293), KY Department for Public Health, $140,000.00

STEPHEN WYATT/MARGARET HICKMAN
Appalachia Cancer Network, (463703), Natl Cancer Institute, $75,000.00

STEPHEN WYATT/MARGARET HICKMAN
Special Populations Network: Appalachia Cancer Network, (464660), Natl Cancer Institute, $1,390,738.00

STEPHEN WYATT/R CLAYTON/F. SCUTCHFIELD
Controlling Cancer in Central Appalachia, (464352), Center for Disease Control and Prevention, $530,500.00

SUSANNE ARNOLD
A Phase III Trial of ALIMTA vs Docetaxel in Patients with Locally Advanced or Metastasic Non-Small Lung Cancer (NSCLC) who were previously treated with Chemotherapy, (464669), Eli Lilly and Company, $2.00

SUSANNE ARNOLD
Paclitaxel., Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer, (464197), Bristol Myers Squibb Company, $2.00

SUSANNE ARNOLD
A randomized, Double-Blind, Phase III Comparative Trial of Two Doses of ZD 1839 in Combination with Paclitaxel and Carboplatin Versus Placebo in Combination with Paclitaxel and Carboplatin in Chemotherapy Patient with Advanced Non-Small Cell Lung Cancer, (464426), AstraZeneca, $2.00

SUSANNE ARNOLD
Phase II Study of BBR 3464 as Treatment in Patients with Sensitive or Refractory Small Lung Cancer after one Prior Chemotherapy Regimen, (464501), Theradex, $1,850.00

SUSANNE ARNOLD
Concurrent Paclitaxel and Radiotherapy for Poor Risk Patients with Inoperable Stage I, II and II Non-Small Cell Lung Cancer, (463721), Bristol Myers Squibb Company, $19,998.00

THOMAS TUCKER/GILBERT FRIEDELL/WILLIAM WAGNER
Cancer Information Service, (463347), Natl Cancer Institute, $1,607,883.00

THOMAS TUCKER/STEPHEN WYATT
National Program of Cancer Registries, (464101), Center for Disease Control and Prevention, $423,711.00

THOMAS TUCKER/STEPHEN WYATT
Surveillance, Epidemiology and End Results Expansion Program, (464634), Natl Cancer Institute, $638,678.00

TIMOTHY MEEKER
A Double-Blind, Randomized, Parallel-Group, Two-Arm, Placebo Controlled, Multicenter Evaluation of CEAVAC (3H1) Anti- Idiotypic Antibody in the Management of Patients, (462698), Titan Pharmaceuticals Inc, $2,183.00

TIMOTHY MEEKER
A Double-Blind, Randomized, Parallel-Group, Two-Arm, Placebo Controlled, Multicenter Evaluation of CEAVAC (3H1) Anti- Idiotypic Antibody in the Management of Patients, (462531), Titan Pharmaceuticals Inc, $1,170.00

WILLIAM REGINE
GI-38EL Phase I/II Evaluation of Radiation and Gemcitabine in Locally Advanced or Metastatic Tumors of the Gastrointestinal Tract, (463063), Eli Lilly and Company, $47,998.00

WILLIAM REGINE
Support of Ongoing Activities with the American College of Radiology NO IAF, (460861), American College of Radiology, $61,350.00

WILLIAM REGINE
A Phase I Study of Low-Dose Upper Abdominal Radiation Therapy (UART) or Whole (W) Art as a Chemosensitizer in Patients with Locally Advanced or Metastatic, (464683), Eli Lilly and Company, $2.00


* Cross-referenced accounts where the project director/s are affiliated with more than one department, college or center
Information Systems
Questions:
 Deborah Davis,  Office of Sponsored Projects Administration, 112 Kinkead Hall, 0057, 257-8311

UK Awards Home    Research    University of Kentucky